As a thrombopoietin receptor agonist medication, Eltrombopag is indicated for treating Thrombocytopenia in pediatric patients and adults enduring chronic immune (idiopathic) thrombocytopenia (ITP), Thrombocytopenia in Patients with Hepatitis C Infection and Severe Aplastic Anemia.
This drug is generally used in the patient having an insufficient response to the splenectomy, immunoglobulins or corticosteroids.
- For ITP: For adults and children (6 to 17 years) with ITP, the recommended starting dose is 50 mg in a day. For children with ITP (1-5 years), the recommended starting dose is 25 mg tablet in a day.
- For Hepatitis C: The recommended starting dose for adult patients with hepatitis C is 25 mg in a day.
- For Severe Aplastic Anaemia (SAA): The recommended starting dose for SAA is 50 mg in a day. If you consume more dose than you should contact a healthcare practitioner immediately.
The commonly reported eltrombopag side effects may include:
- Adult Patient with ITP: Urinary tract infection, vomiting, upper respiratory tract infection, increased ALT, nausea, diarrhea, and myalgia.
- Pediatric patients with ITP: Negative reactions of eltrombopag 25 mg are nasopharyngitis and upper respiratory tract infection.
- Patients with chronic hepatitis C-associated thrombocytopenia: Cough, insomnia, pruritus, alopecia, myalgia, chills, peripheral edema, diarrhea, nausea, pyrexia, and headache.
- Patients with severe aplastic anemia: Cough headache, nausea, diarrhea, and fatigue are common reactions.